A New Day at FDA: Commissioner Makary Arrives, as Does a Major RIF - What Does It Mean for Stakeholders?

When:
People:
Stuart M. Pape, Michael M. Gaba, Chad A. Landmon

This webinar was previously recorded. Click here to access the recording.

A few days after his Senate confirmation and shortly before he is sworn in as FDA Commissioner, Dr. Marty Makary will be joining an FDA reeling from historic personnel cuts and an internal reorganization announced by HHS Secretary Kennedy. Our experienced team will explore these significant developments and what they likely mean for stakeholders and public health.

Agenda

  • What is Dr. Makary’s likely agenda
  • What are the likely impacts of personnel cuts?
  • How might user-fee programs be affected?
  • How should regulated industries adjust strategy to account for these changes and expected policy shifts?